abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
94264: Zika Virus Antibody (IgM), MAC-ELISA Print View
Zika Virus Ab (IgM) IA     
Pregnant (Y/N)      
Travel in Zika Region?      
Resident of Zika Region?      
Clinical Signs/Symptoms?      
Date of Onset (mm/dd/yy)      
Patient State      

PRIMARY
1 Serum 3 (1) mL   Frozen - 30 Day(s)/Refrigerated - 48 Hour(s)  
ALTERNATE

Testing should only be performed on individuals meeting Centers for Disease Control and Prevention (CDC) Zika virus clinical criteria (e.g., clinical signs and symptoms associated with Zika virus infection) and/or CDC Zika virus epidemiological criteria (e.g., history of residence in, or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiologic criteria for which Zika virus testing may be indicated, such as possible sexual transmission). Most people with Zika virus infection are asymptomatic. Symptomatic individuals typically experience a mild illness characterized by fever, joint pain, rash, or conjunctivitis. Clinical illness is usually self-limited and lasts a week or less. Not all symptomatic patients report all of these clinical findings, and Zika manifestations overlap significantly with those seen in other viral infections. The incubation period is unclear, but likely to be several days. Symptoms generally resolve on their own within a week. Zika IgM levels over the course of illness are not well characterized. IgM levels are variable, but generally are positive starting near day four post onset of symptoms and continuing for 12 or more weeks following initial infection. Zika Virus IgM MAC-ELISA should be tested as a part of a multi-test algorithm recommended by the CDC. http://www.cdc.gov/zika/hc-providers/index.html Assay results are for the presumptive identification of IgM antibodies to Zika virus. Pregnant women at risk for Zika virus in the U.S. and in endemic areas are of special concern due to the increased incidence of babies with microcephaly or other congenital defects if mothers are infected during pregnancy. Please refer to the CDC guidelines for the appropriate testing in pregnant women. http://www.cdc.gov/zika/hc-providers/pregnant-woman.html Zika infection shares epidemiologic and clinical features with chikungunya, dengue, and

Order Zika tests separately from other tests - on a separate
requisition.

Collect blood in a serum separator vacutainer tube (preferred)
or a standard red-top.

Allow blood to clot at room temperature.

Blood collection tube should be centrifuged as soon as possible and
serum transferred to a plastic tube, in order to avoid hemolysis.
Mark as "Irreplaceable Specimen" and follow Irreplaceable
Specimen procedures.

Transport refrigerated (cold packs) to local Quest Diagnostics
accessioning laboratory. IMPORTANT: If sample cannot be transported
refrigerated to accessioning laboratory within 48 hours, serum should
be frozen at or below -20 degrees Celsius.

Specimens must not be left in lock boxes.
Setup Schedule
Monday-Saturday

Reported (Analytical Time)
Next day

CPT Code
86790

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
This test is only for use under the Food and Drug Adminstration's (FDA) Emergency Use Authorization Transport Temperature: Refrigerated Reject Criteria: Serum received in spun SSTs






1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database